Choroideremia Treatment Market

Choroideremia Treatment Market: Rising Treatment Adoption for Choroideremia Disease to Drive Choroideremia Treatment Market Growth

Market Overview

Choroideremia results in progressive loss of vision and is more prominent in males. The first symptom of choroideremia is usually night blindness that occurs at an early stage.

Vision loss occurs due to degeneration of light-sensitive tissue cell. Nearly every patient with choroideremia develops progressive reduction of vision at a later stage.

As per Center for Disease Control and Prevention (CDC), 1 in 50,000-100,000 among U. S. population is suffering from choroideremia disease. The Choroideremia disease is a genetic, rare and degenerative disorder with lack of specific treatment and currently there is unmet demand of novel treatments in the choroideremia treatment market.

Covid-19 will have a significant impact on the choroideremia treatment market due to delay of diagnosis and treatment of patients suffering from the choroideremia. There has been a considerable priority shift in the focus of healthcare system across the globe owing to Covid-19 pandemic.

Covid-19 burden on the global healthcare system is expected to show short-term negative impact on the treatment development and adoption in choroideremia treatment market.

However, the impact will be short-term and post-COVID 19 pandemic, choroideremia treatment market will show a significant surge owing to increase in treatment adoption.The rise in prevalence of choroideremia is expected to propel the choroideremia treatment market growth. 

In addition, increased awareness and treatment seeking rate is expected to boost the treatment demand in the choroideremia treatment market. Currently, several leading biopharmaceutical players are undergoing clinical trial for disease-specific treatment like NightstaRx Ltd., University of oxford and this trend will fuel the growth of choroideremia treatment market during the forecast period.

Strategic collaboration and mergers among key players to develop treatment options is anticipated to propel choroideremia treatment market growth.

Limited research and development funding activities is expected to hamper growth of choroideremia treatment market. In addition, Side-effects and post-operation complications are expected to become barrier in the growth of choroideremia treatment market.

Unskilled professional, mostly in emerging and developing regions is predicted to hinder the growth of choroideremia treatment market. The global choroideremia treatment market is classified based on therapy, route of administration, distribution channel and region.

Increasing prevalence and availability of treatment option to control the complications of choroideremia has a major contributor towards the growth of the choroideremia treatment market.

Based on the treatment type gene therapy is expected to dominate the choroideremia treatment market. Opthalmic route of administration holds the major share of revenue in choroideremia treatment market as compared to other route of administration. 

Based on the distribution channel, hospital pharmacies is projected to generate the highest revenue share followed by the retail pharmacies in the choroideremia treatment market. However, online pharmacy is estimated to have significant growth in the coming decade due to increasing adoption of e-commerce platforms.

Choroideremia treatment market is dominated by North America in terms of revenue owing to higher rate of prevalence in the region. Europe’s choroideremia treatment market is projected to have moderate growth due to advanced treatments and more awareness among the population.

With an increase in patient population and per capita income, Asia Pacific region is expected to be the fastest-growing market. The Middle East and Africa regions least lucrative market owing to poor healthcare access in the region.

Some key players contributing in choroideremia treatment market are

  • Novartis AG,
  • Spark Therapeutics,
  • Bluebird Bio Inc.,
  • Biogen,
  • Copernicus Therapeutics, Inc.,
  • 4D Molecular Therapeutics,
  • Wize Pharma Inc.,
  • Retina Implant AG,
  • Hoffmann-La Roche Ltd,
  • Pixium Vision

The research report choroideremia treatment market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report on choroideremia treatment market provides analysis and information according to market segments such as drug class, route of administration, application, and region.

The report covers exhaust analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Europe (Germany, Italy, France, U.K, Spain, Russia)
  • East Asia (China, Japan, South Korea)
  • South Asia (India, ASEAN)
  • Oceania (Australia, New Zealand)
  • Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current, and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

choroideremia treatment market is segmented

By therapy

  • Topical Carbonic Anhydrase Inhibitor
  • Dorzolamide
  • Gene Therapy
  • Luxturna (voretigene neparvovec-rzyl)
  • Antioxidants
  • Lutein

By administration

  • Oral 
  • Opthalmic
  • Intravenous

By distribution

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drugstores
  • Online Pharmacies

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports


Choroideremia Treatment Market